AUTHOR CORRECTION
Volume 57, no. 4, e01844-18, 2019, https://doi.org/10.1128/JCM.01844-18. This article was published on 28 March 2019 with a byline lacking Julia Lu. The byline was updated in the version posted on 22 April 2020.
. 2020 Jun 24;58(7):e00857-20. doi: 10.1128/JCM.00857-20
Correction for Han et al., “In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir”
Bin Han
a, Bandita Parhy
a, Julia Lu
a, Eric Zhou
a, David Hsieh
a, Gregory Camus
a, Ross Martin
a, Evguenia S Svarovskaia
a, Hongmei Mo
a, Hadas Dvory-Sobol
a,✉
Evguenia S Svarovskaia
aGilead Sciences, Inc., Foster City, California, USA
Find articles by Evguenia S Svarovskaia
Hadas Dvory-Sobol
aGilead Sciences, Inc., Foster City, California, USA
Find articles by Hadas Dvory-Sobol
aGilead Sciences, Inc., Foster City, California, USA
✉
Address correspondence to Hadas Dvory-Sobol, Hadas.Dvory-Sobol@Gilead.com.
Citation Han B, Parhy B, Lu J, Zhou E, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H. 2020. Correction for Han et al., “In vitro susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangenotypic NS3/4A inhibitor voxilaprevir.” J Clin Microbiol 58:e00857-20. https://doi.org/10.1128/JCM.00857-20.
✉
Corresponding author.
Collection date 2020 Jul.
PMCID: PMC7315032 PMID: 32580966
This corrects the article "In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir" in volume 57, e01844-18.